Hospital and Internal Medicine Podcast
11min2022 JAN 28
播放聲音
喜歡
評論
分享

詳細信息

Thedouble-blind, randomized phase III EMPEROR-Preservedtrial showed a benefit of the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). Now let us dig a bit more into those headlines.

查看更多